MRI in the assessment and monitoring of multiple sclerosis: an update on best practice

Magnetic resonance imaging (MRI) has developed into the most important tool for the diagnosis and monitoring of multiple sclerosis (MS). Its high sensitivity for the evaluation of inflammatory and neurodegenerative processes in the brain and spinal cord has made it the most commonly used technique for the evaluation of patients with MS. Moreover, MRI has become a powerful tool for treatment monitoring, safety assessment as well as for the prognostication of disease progression. Clinically, the use of MRI has increased in the past couple decades as a result of improved technology and increased availability that now extends well beyond academic centers. Consequently, there are numerous studies supporting the role of MRI in the management of patients with MS. The aim of this review is to summarize the latest insights into the utility of MRI in MS.

[1]  A J Thompson,et al.  Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis , 2003, Multiple sclerosis.

[2]  À. Rovira,et al.  Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event , 2014, PloS one.

[3]  Michael Dayan,et al.  Profilometry: A new statistical framework for the characterization of white matter pathways, with application to multiple sclerosis , 2016, Human brain mapping.

[4]  Xu Li,et al.  Mapping magnetic susceptibility anisotropies of white matter in vivo in the human brain at 7T , 2012, NeuroImage.

[5]  Yi Wang,et al.  Quantitative MR susceptibility mapping using piece‐wise constant regularized inversion of the magnetic field , 2008, Magnetic resonance in medicine.

[6]  Maria Assunta Rocca,et al.  Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis , 2013, Neurology.

[7]  D. Pelletier,et al.  Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? , 2016, Current opinion in neurology.

[8]  V. Tomassini,et al.  Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis , 2006, Journal of Neurology.

[9]  O. Kantarci,et al.  Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis , 2009 .

[10]  Carsten Lukas,et al.  Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.

[11]  C. Laule,et al.  Long T2 water in multiple sclerosis: What else can we learn from multi-echo T2 relaxation? , 2007, Journal of Neurology.

[12]  S. Hussein,et al.  Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years , 2013, American Journal of Neuroradiology.

[13]  F. Barkhof,et al.  MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  Burkhard Mädler,et al.  Myelin water imaging: Implementation and development at 3.0T and comparison to 1.5T measurements , 2009, Magnetic resonance in medicine.

[15]  M. Sormani,et al.  Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[16]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  Giuseppe Iannucci,et al.  MR correlates of cerebral atrophy in patients with multiple sclerosis , 2002, Journal of Neurology.

[18]  Jacqueline Palace,et al.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  Massimiliano Calabrese,et al.  Measurement and clinical effect of grey matter pathology in multiple sclerosis , 2012, The Lancet Neurology.

[20]  D. Miller,et al.  Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. , 2014, Multiple sclerosis and related disorders.

[21]  E. Cristiano,et al.  Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes , 2013, Multiple sclerosis.

[22]  Y Wang,et al.  Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection , 2016, American Journal of Neuroradiology.

[23]  Massimo Filippi,et al.  Seven‐tesla phase imaging of acute multiple sclerosis lesions: A new window into the inflammatory process , 2013, Annals of neurology.

[24]  M. Steenwijk,et al.  MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update , 2015, Clinical Neuroradiology.

[25]  O. Ciccarelli,et al.  MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES , 2016, The Lancet Neurology.

[26]  G Tedeschi,et al.  Brain atrophy and lesion load in a large population of patients with multiple sclerosis , 2005, Neurology.

[27]  D. Chard,et al.  Grey matter pathology in clinically early multiple sclerosis: Evidence from magnetic resonance imaging , 2009, Journal of the Neurological Sciences.

[28]  Yan Zhang,et al.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM) , 2016, Journal of magnetic resonance imaging : JMRI.

[29]  Wu Liu,et al.  Lesion Activity on Brain MRI in a Chinese Population with Unilateral Optic Neuritis , 2015, PloS one.

[30]  C. Tan.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.

[31]  Tracy R. Melzer,et al.  Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis , 2015, Psychiatry Research: Neuroimaging.

[32]  Hellmut Merkle,et al.  Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. , 2012, Radiology.

[33]  Pascal Spincemaille,et al.  Feasibility and reproducibility of whole brain myelin water mapping in 4 minutes using fast acquisition with spiral trajectory and adiabatic T2prep (FAST‐T2) at 3T , 2016, Magnetic resonance in medicine.

[34]  L. Kappos,et al.  Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis , 2015, Journal of Neurology.

[35]  Frederik Barkhof,et al.  Imaging of White Matter Lesions , 2002, Cerebrovascular Diseases.

[36]  Sheena L. Dupuy,et al.  MRI detection of hypointense brain lesions in patients with multiple sclerosis: T1 spin-echo vs. gradient-echo. , 2015, European journal of radiology.

[37]  S W Atlas,et al.  Multiple sclerosis: gadolinium enhancement in MR imaging. , 1986, Radiology.

[38]  Gregory F. Wu,et al.  The contemporary spectrum of multiple sclerosis misdiagnosis , 2016, Neurology.

[39]  James McIninch,et al.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients , 2014, Annals of clinical and translational neurology.

[40]  David Pitt,et al.  Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions , 2013, PloS one.

[41]  J H Simon,et al.  A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.

[42]  A. Thompson,et al.  Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study , 2004, Multiple sclerosis.

[43]  R A Betensky,et al.  Predicting short-term disability in multiple sclerosis , 2007, Neurology.

[44]  O. Ciccarelli,et al.  MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis , 2015, The Lancet Neurology.

[45]  Su-Hyun Kim,et al.  Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder , 2012, Multiple sclerosis international.

[46]  K Ambarki,et al.  Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis , 2013, American Journal of Neuroradiology.

[47]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients , 2015, Nature Reviews Neurology.

[48]  F. Barkhof,et al.  MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[49]  R. Scheyer,et al.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.

[50]  V. Tomassini,et al.  Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience , 2005, Neurological Sciences.

[51]  F. Barkhof,et al.  Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[52]  A J Thompson,et al.  Multiple sclerosis lesion detection in the brain: A comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo , 1997, Neurology.

[53]  Jiwon Oh,et al.  Spinal Cord MRI in Multiple Sclerosis. , 2018, Neurologic clinics.

[54]  M. Filippo,et al.  Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  À. Rovira,et al.  Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. , 2016, Seminars in ultrasound, CT, and MR.

[56]  F. Causin,et al.  The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset , 2015, PloS one.

[57]  D. Arnold,et al.  2010 McDonald criteria for diagnosing pediatric multiple sclerosis , 2012, Annals of neurology.

[58]  Roland G. Henry,et al.  The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative , 2016, Nature Reviews Neurology.

[59]  R. Benedict,et al.  The thalamus and multiple sclerosis , 2013, Neurology.

[60]  Marco Rovaris,et al.  Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study , 2011, Multiple sclerosis.

[61]  D. Ramasamy,et al.  A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients , 2016, Multiple sclerosis.

[62]  Su-Hyun Kim,et al.  The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders , 2014, Multiple sclerosis.

[63]  J. De Keyser,et al.  T2 lesions and rate of progression of disability in multiple sclerosis , 2010, European journal of neurology.

[64]  R. Gold,et al.  Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy , 2017, Multiple sclerosis.

[65]  D. Okuda,et al.  Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis , 2015, Spinal Cord.

[66]  R. Kinkel,et al.  Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. , 2014, Multiple sclerosis and related disorders.

[67]  Sukru Mehmet Erturk,et al.  Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. , 2007, AJR. American journal of roentgenology.

[68]  David H. Miller,et al.  Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord. , 2014, Brain : a journal of neurology.

[69]  L. Jones,et al.  B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene , 2016 .

[70]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[71]  A. Dale,et al.  One-Year Brain Atrophy Evident in Healthy Aging , 2009, The Journal of Neuroscience.

[72]  B. Neumayer,et al.  Quantitative MR imaging in fracture dating--Initial results. , 2016, Forensic science international.

[73]  David H. Miller,et al.  Cervical cord lesion load is associated with disability independently from atrophy in MS , 2015, Neurology.

[74]  F. Lublin,et al.  Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS , 2016, PloS one.

[75]  R. Barker,et al.  LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[76]  S. T. Govindarajan,et al.  Beyond focal cortical lesions in MS , 2015, Neurology.

[77]  Mitchell A. Cooper,et al.  T2prep three‐dimensional spiral imaging with efficient whole brain coverage for myelin water quantification at 1.5 tesla , 2012, Magnetic resonance in medicine.

[78]  Nick C Fox,et al.  Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[79]  L S Honig,et al.  Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[80]  D. Alsop,et al.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study , 2009, Journal of the Neurological Sciences.

[81]  Ken E Sakaie,et al.  The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis , 2015, Multiple sclerosis.

[82]  Rohit Bakshi,et al.  Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[83]  Heidi Johansen-Berg,et al.  Myelin water imaging reflects clinical variability in multiple sclerosis , 2012, NeuroImage.

[84]  M. Freedman,et al.  MS, MRI, and the 2010 McDonald criteria , 2012, Neurology.

[85]  M. Dwyer,et al.  Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis , 2015, Journal of Neurology.

[86]  F. Barkhof,et al.  Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome , 2014, Multiple sclerosis.

[87]  V. Fleischer,et al.  Structural correlates for fatigue in early relapsing remitting multiple sclerosis , 2016, European Radiology.

[88]  M. Battaglini,et al.  Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[89]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[90]  P. Matthews,et al.  A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[91]  F. Barkhof,et al.  Clinical correlations of brain lesion distribution in multiple sclerosis , 2009, Journal of magnetic resonance imaging : JMRI.

[92]  Thorarin A Bjarnason,et al.  Myelin water measurement in the spinal cord , 2009, Magnetic resonance in medicine.

[93]  M. Fukunaga,et al.  Sensitivity of MRI resonance frequency to the orientation of brain tissue microstructure , 2010, Proceedings of the National Academy of Sciences.

[94]  F. Barkhof,et al.  Does high field MRI allow an earlier diagnosis of multiple sclerosis? , 2008, Journal of Neurology.

[95]  Yi Wang,et al.  Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker , 2014, Magnetic resonance in medicine.

[96]  A. Osborn.  Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome , 2010 .

[97]  F. Barkhof,et al.  Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. , 2014, Current opinion in neurology.

[98]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process , 2015, Nature Reviews Neurology.

[99]  A. Traboulsee,et al.  The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis , 2011, Multiple sclerosis.

[100]  M. Sormani,et al.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.

[101]  R. Rudick,et al.  Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.

[102]  L. Nagae,et al.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities , 2015, Multiple sclerosis international.

[103]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[104]  W Craelius,et al.  Iron deposits surrounding multiple sclerosis plaques. , 1982, Archives of pathology & laboratory medicine.

[105]  L. Durelli,et al.  MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[106]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[107]  Hellmut Merkle,et al.  Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. , 2011, Brain : a journal of neurology.

[108]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[109]  E. Waubant,et al.  Longitudinal associations between brain structural changes and fatigue in early MS. , 2016, Multiple sclerosis and related disorders.

[110]  Margit Jehna,et al.  Quantitative susceptibility mapping in multiple sclerosis. , 2013, Radiology.

[111]  Massimo Filippi,et al.  Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. , 2016, The Journal of clinical investigation.

[112]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[113]  Byung Jo Kim,et al.  Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? , 2013, Multiple sclerosis.

[114]  Bruno Alfano,et al.  Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients , 2015, PloS one.

[115]  A. Traboulsee,et al.  Longitudinal changes in myelin water fraction in two MS patients with active disease , 2009, Journal of the Neurological Sciences.

[116]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[117]  Simon Hametner,et al.  Iron and neurodegeneration in the multiple sclerosis brain , 2013, Annals of neurology.

[118]  J A Frank,et al.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. , 2006, AJNR. American journal of neuroradiology.

[119]  Cristian Donos,et al.  A connectomics approach combining structural and effective connectivity assessed by intracranial electrical stimulation , 2016, NeuroImage.

[120]  A. Thompson,et al.  Spinal cord MRI using multi‐array coils and fast spin echo , 1993, Neurology.

[121]  R. Rudick,et al.  Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.

[122]  L. Kappos,et al.  MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice , 2010, American Journal of Neuroradiology.

[123]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[124]  Susan A. Gauthier,et al.  Measuring longitudinal myelin water fraction in new multiple sclerosis lesions , 2015, NeuroImage: Clinical.

[125]  Shigeru Furui,et al.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. , 2015, Radiology.

[126]  H. Lassmann,et al.  Pathology of multiple sclerosis and related inflammatory demyelinating diseases. , 2014, Handbook of clinical neurology.

[127]  S. Karlik,et al.  Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis , 1992, Annals of neurology.

[128]  Thomas E. Nichols,et al.  Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis , 2014, Multiple sclerosis.

[129]  P. Narayana,et al.  Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data , 2015, Multiple sclerosis and related disorders.

[130]  S Ropele,et al.  Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis , 2011, Multiple sclerosis.

[131]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.

[132]  Turi O. Dalaker,et al.  Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[133]  Julien Cohen-Adad,et al.  g-Ratio weighted imaging of the human spinal cord in vivo , 2017, NeuroImage.

[134]  K. Schmierer,et al.  Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.

[135]  C. Pozzilli,et al.  One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.

[136]  T. Scott,et al.  Short-term prognosis in early relapsing-remitting multiple sclerosis , 2000, Neurology.

[137]  Maija E. Rossi,et al.  Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI. , 2015, Clinical imaging.

[138]  D. Reich,et al.  Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis , 2016, Multiple sclerosis.

[139]  D. Goodin,et al.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.

[140]  Mike P. Wattjes,et al.  Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics , 2014, Journal of Neurology.

[141]  O Ciccarelli,et al.  Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome , 2017, Multiple sclerosis.

[142]  B. Mädler,et al.  Multicenter measurements of myelin water fraction and geometric mean T2: Intra‐ and intersite reproducibility , 2013, Journal of magnetic resonance imaging : JMRI.

[143]  M. Wattjes,et al.  Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good? , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[144]  Vinzenz Fleischer,et al.  Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2 , 2016, Brain Imaging and Behavior.

[145]  Bing Wu,et al.  Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition , 2011, NeuroImage.

[146]  Y Wang,et al.  Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation , 2016, American Journal of Neuroradiology.

[147]  Brian K. Rutt,et al.  Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI , 2012, NeuroImage.